GH1 and medulloblastoma: Analyses of GH-treated survivors of childhood medulloblastoma followed up in the NCGS determined a medulloblastoma recurrence rate of 7.2% (35), whereas the KIGS database reported 92% relapse-free survival at 4.6 years (36).